Zobrazeno 1 - 10
of 14
pro vyhledávání: '"L. I. Feiskhanova"'
Autor:
L. I. Feiskhanova, D. I. Abdulganieva
Publikováno v:
Klinicist, Vol 14, Iss 3-4, Pp 36-42 (2021)
The objective of the study – identify early preclinical signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis.Material and methods. We examined 142 people with verified rheumatic diseases. All patients wer
Externí odkaz:
https://doaj.org/article/15a76c353c2841218c1ab55197f1d196
Autor:
S. A. Shalnova, V. N. Belov, M. N. Valiakhmetov, N. G. Veselovskaya, N. V. Voronina, A. V. Dmitriev, E. V. Efremova, L. О. Minushkina, A. М. Naydich, V. Yu. Pavlova, Ya. M. Pakhomov, A. Е. Rivin, L. I. Feiskhanova, Е. V. Khorolets, О. P. Askerko, E. Z. Topuridze
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 17, Iss 2, Pp 81-87 (2018)
Most cardiovascular diseases (CVD) are of atherosclerotic origin, and lipid disorders play significant role, setting up the cardiovascular continuum, together with other risk factors. It also known that decrease of low density lipoproteins cholestero
Externí odkaz:
https://doaj.org/article/507468b93d1a4c868f3731bd43bdaa4e
EFFECT OF RITUXIMAB ON CARDIAC ELECTROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Autor:
L. I. Feiskhanova
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 5, Pp 600-602 (2018)
Rheumatoid arthritis (RA) is an autoimmune rheumatic disease characterized by damage not only to the joints, but also to the viscera, including the heart. The cardiovascular risk in patients with RA is 1.5 times higher than that in the general popula
Externí odkaz:
https://doaj.org/article/27160e9d7a00403388e2a0f9ef425506
Autor:
A A Malov, L I Feiskhanova
Publikováno v:
Системные гипертензии, Vol 13, Iss 2, Pp 24-27 (2016)
In article possibility of an assessment of efficiency of therapy by the reproduced drug Mertenil of production of JSC Gideon Richter (Hungary) appointed for the purpose of primary prevention of the cardiovascular diseases. Increase of level of lipopr
Externí odkaz:
https://doaj.org/article/559497bb2656405bb0b786a27b61da81
Autor:
L I Feiskhanova, A A Malov
Publikováno v:
Системные гипертензии, Vol 13, Iss 2, Pp 88-90 (2016)
The article assesses the effectiveness of therapy generics Bidop® production of Gedeon Richter (Hungary), designated to improve diastolic function, and treatment of heart failureof patients with hypertrophic cardiomyopathy with predominant hypertrop
Externí odkaz:
https://doaj.org/article/c9fc225802754b13a3bb5d0b6908f6f4
Autor:
L. R. Khaliullina, L. I. Feiskhanova
Publikováno v:
Clinical Medicine (Russian Journal). 96:597-603
The review covers the modern scientific literature about cardiovascular disease in patients with rheumatic diseases. Rheumatic diseases are associated with chronic inflammation, most often joints, skin, eyes, lungs, kidneys and circulatory system. Ca
Autor:
О. P. Askerko, E. V. Efremova, A. М. Naydich, L. I. Feiskhanova, V. N. Belov, A. Е. Rivin, E. Z. Topuridze, A. V. Dmitriev, Е. V. Khorolets, Ya. M. Pakhomov, M. N. Valiakhmetov, N. G. Veselovskaya, V. Yu. Pavlova, L. О. Minushkina, S. A. Shalnova, N. V. Voronina
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 17, Iss 2, Pp 81-87 (2018)
Most cardiovascular diseases (CVD) are of atherosclerotic origin, and lipid disorders play significant role, setting up the cardiovascular continuum, together with other risk factors. It also known that decrease of low density lipoproteins cholestero
Publikováno v:
Practical medicine. 16:95-98
Publikováno v:
Practical medicine. 16:99-101
Autor:
L I Feiskhanova, A A Malov
Publikováno v:
Системные гипертензии, Vol 13, Iss 2, Pp 24-27 (2016)
In article possibility of an assessment of efficiency of therapy by the reproduced drug Mertenil of production of JSC Gideon Richter (Hungary) appointed for the purpose of primary prevention of the cardiovascular diseases. Increase of level of lipopr